Acadia Pharmaceuticals (ACAD) Other Gross PP&E Adjustments (2016 - 2025)
Acadia Pharmaceuticals (ACAD) has 15 years of Other Gross PP&E Adjustments data on record, last reported at -$68.4 million in Q4 2025.
- For Q4 2025, Other Gross PP&E Adjustments fell 14.74% year-over-year to -$68.4 million; the TTM value through Dec 2025 reached -$68.4 million, down 14.74%, while the annual FY2025 figure was -$68.4 million, 14.74% down from the prior year.
- Other Gross PP&E Adjustments reached -$68.4 million in Q4 2025 per ACAD's latest filing, up from -$79.5 million in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at -$52.8 million in Q4 2022 and bottomed at -$88.7 million in Q4 2023.
- Average Other Gross PP&E Adjustments over 5 years is -$71.0 million, with a median of -$70.8 million recorded in 2022.
- Peak YoY movement for Other Gross PP&E Adjustments: tumbled 181.27% in 2021, then soared 32.85% in 2024.
- A 5-year view of Other Gross PP&E Adjustments shows it stood at -$53.4 million in 2021, then rose by 0.98% to -$52.8 million in 2022, then plummeted by 67.92% to -$88.7 million in 2023, then skyrocketed by 32.85% to -$59.6 million in 2024, then dropped by 14.74% to -$68.4 million in 2025.
- Per Business Quant database, its latest 3 readings for Other Gross PP&E Adjustments were -$68.4 million in Q4 2025, -$79.5 million in Q3 2025, and -$81.0 million in Q2 2025.